Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Pfizer Venture Investments
AddedFeb 13, 2024
UpdatedJul 11, 2026
Pfizer Venture Investments

Pfizer Venture Investments

Operating

Pfizer Venture Investments: A strategic life science VC, investing in transformative medicines and technologies.

Location
New York City, NY, US
Founded
2004
Firm
Compare
Portfolio
Employees
Website

Investments

Flare Therapeutics
Flare Therapeutics
Series C

Total Raised

$290M

Rounds

3

Series C$85MJune 2026
Series B$123MMarch 2023
Oblenio Bio
Oblenio Bio
Series B

Total Raised

$62M

Rounds

1

Series B$62MJune 2026
RefleXion Medical
RefleXion Medical

Total Raised

$675.1M

Rounds

11

Series Unknown$105MNovember 2023
Series Unknown$80MMarch 2022
ReCode Therapeutics
ReCode Therapeutics

Total Raised

$521.8M

Rounds

6

Series B$50MSeptember 2023
Series B$120MJune 2022
Series B$259.8MOctober 2021
Nimbus Therapeutics
Nimbus Therapeutics
Public

Total Raised

$637M

Rounds

9

Private Equity$210MSeptember 2023
Late Stage Private$125MSeptember 2022
Crossbow Therapeutics
Crossbow Therapeutics
Series B

Total Raised

$157M

Rounds

2

Series A$80MJuly 2023
Mozart Therapeutics
Mozart Therapeutics

Total Raised

$80M

Rounds

2

Series A$25MJune 2023
Mediar Therapeutics
Mediar Therapeutics

Total Raised

$145.6M

Rounds

4

Series A$85MMarch 2023
Ribon Therapeutics
Ribon Therapeutics

Total Raised

$259M

Rounds

7

Series Unknown$25MDecember 2022
Jnana Therapeutics
Jnana Therapeutics

Total Raised

$207M

Rounds

3

Series C$107MNovember 2022
Oxford Sciences Innovation
Oxford Sciences Innovation

Total Raised

$319.8M

Rounds

5

Series A$37.5MOctober 2022
Capstan Therapeutics
Capstan Therapeutics

Total Raised

$165M

Rounds

2

Series A$102MSeptember 2022
Autobahn Therapeutics
Autobahn Therapeutics

Total Raised

$108.7M

Rounds

2

Series Unknown$32.7MSeptember 2022
MindImmune Therapeutics
MindImmune Therapeutics

Total Raised

$13.7M

Rounds

3

Series A$12.4MJune 2022
DEM Biopharma
DEM Biopharma

Total Raised

$70M

Rounds

1

Series A$70MJune 2022
Triana Biomedicines
Triana Biomedicines

Total Raised

$160.8M

Rounds

4

Series A$110MApril 2022
TRex Bio
TRex Bio

Total Raised

$85M

Rounds

2

Series A$26MMarch 2022
Arkuda Therapeutics
Arkuda Therapeutics

Total Raised

$108M

Rounds

3

Series B$64MFebruary 2022
Kestrel Therapeutics
Kestrel Therapeutics

Total Raised

$40M

Rounds

1

Series A$40MDecember 2021
Parthenon Therapeutics
Parthenon Therapeutics

Total Raised

$65M

Rounds

1

Series A$65MNovember 2021